WASHINGTON, April 13, 2018 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today
that the U.S. Court of Appeals for the Federal
Circuit affirmed the U.S. District Court for the District
of Delaware's decision that West
Ward Pharmaceuticals, a subsidiary of Hikma Pharmaceuticals,
infringed Vanda's U.S. Patent number 8,586,610 (the '610 Patent)
for Fanapt®. The '610 Patent is set to expire
November 2, 2027.
About Vanda Pharmaceuticals Inc.
Vanda is a global biopharmaceutical company focused on the
development and commercialization of innovative therapies to
address high unmet medical needs and improve the lives of
patients. For more on Vanda Pharmaceuticals Inc., please
visit www.vandapharma.com.
About Fanapt®
For full U.S. Prescribing Information for Fanapt®,
including indication, Boxed Warnings and Important Safety
Information, visit our Web site at www.fanapt.com.
Investor Contact:
Jim
Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
View original
content:http://www.prnewswire.com/news-releases/vanda-wins-appeal-case-on-fanapt-300629612.html
SOURCE Vanda Pharmaceuticals Inc.